Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin

Yi, 2014, Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells, Proc Natl Acad Sci U S A, 111, E2182, 10.1073/pnas.1404943111 Valero, 1996, Locally advanced breast cancer, Oncologist, 1, 8, 10.1634/theoncologist.1-1-8 Singletary, 2002, Revision of the American Joint Committee on Cancer staging system for breast cancer, J Clin Oncol, 20, 3628, 10.1200/JCO.2002.02.026 Specht, 2009, Neoadjuvant chemotherapy for locally advanced breast cancer, Semin Radiat Oncol, 19, 222, 10.1016/j.semradonc.2009.05.001 Liu, 2010, Neoadjuvant therapy for breast cancer, J Surg Oncol, 101, 283, 10.1002/jso.21446 Cleator, 2002, The biology of neoadjuvant chemotherapy for breast cancer, Endocr Relat Cancer, 9, 183, 10.1677/erc.0.0090183 Mamounas, 2003, Neoadjuvant chemotherapy for operable breast cancer: is this the future?, Clin Breast Cancer, 4, s10, 10.3816/CBC.2003.s.010 Sinclair, 2010, Primary systemic chemotherapy for inflammatory breast cancer, Cancer, 116, s2821, 10.1002/cncr.25166 Singh, 2010, Cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, Oncogene, 29, 4741, 10.1038/onc.2010.215 Eyler, 2008, Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis, J Clin Oncol, 26, 2839, 10.1200/JCO.2007.15.1829 Crowder, 2014, Cancer stem cells under hypoxia as a chemoresistance factor in breast and brain, Curr Pathobiol Rep, 2, 33, 10.1007/s40139-013-0035-6 Diehn, 2009, Association of reactive oxygen species levels and radioresistance in cancer stem cells, Nature, 458, 780, 10.1038/nature07733 O'Brien, 2011, Breast cancer stem cells and their role in resistance to endocrine therapy, Horm Cancer, 2, 91, 10.1007/s12672-011-0066-6 Li, 2008, Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy, J Natl Cancer Inst, 100, 672, 10.1093/jnci/djn123 Creighton, 2009, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc Natl Acad Sci U S A, 106, 13820, 10.1073/pnas.0905718106 Tanei, 2009, Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers, Clin Cancer Res, 15, 4234, 10.1158/1078-0432.CCR-08-1479 Lin, 2012, CD44+/CD24− phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma, J Exp Clin Cancer Res, 31, 59, 10.1186/1756-9966-31-59 Alamgeer, 2014, Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer, Breast Cancer Res, 16, R44, 10.1186/bcr3648 Moitra, 2011, Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development, Clin Pharmacol Ther, 89, 491, 10.1038/clpt.2011.14 Gottesman, 2014, Multidrug resistance in cancer: role of ATP–dependent transporters, Nat Rev Cancer, 2, 48, 10.1038/nrc706 Krishna, 2000, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs, Eur J Pharm Sci, 11, 265, 10.1016/S0928-0987(00)00114-7 Yang, 2013, Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype, Mol Cells, 36, 368, 10.1007/s10059-013-0191-x Li, 2013, Vascular endothelial growth factor induces multidrug resistance-associated protein 1 overexpression through phosphatidylinositol-3-kinase/protein kinase B signaling pathway and transcription factor specificity protein 1 in BGC823 cell line, Acta Biochim Biophys Sin (Shanghai), 45, 656, 10.1093/abbs/gmt062 Scotto, 2003, Transcriptional regulation of ABC drug transporters, Oncogene, 22, 7496, 10.1038/sj.onc.1206950 Safe, 2005, Sp1 transcription factor family and its role in cancer, Eur J Cancer, 41, 2438, 10.1016/j.ejca.2005.08.006 Kolesnikoff, 2014, Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition, J Biol Chem, 289, 11194, 10.1074/jbc.M113.529172 Abdelrahim, 2004, Role of Sp1 proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells, Cancer Res, 64, 6740, 10.1158/0008-5472.CAN-04-0713 Wang, 2007, Expression and prognostic value of transcriptional factor Sp1 in breast cancer, Ai Zheng, 26, 996 Zhao, 2013, Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts, Oncol Rep, 30, 1782, 10.3892/or.2013.2627 Zhang, 2012, Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells, Cancer Res, 72, 4178, 10.1158/0008-5472.CAN-11-3983 Chatterjee, 2001, Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons, Ann Neurol, 49, 345, 10.1002/ana.71 Leiman, 2011, Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration, J Neurosci, 31, 6858, 10.1523/JNEUROSCI.0710-11.2011 1993, 161 Kuerer, 1999, Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy, J Clin Oncol, 17, 460, 10.1200/JCO.1999.17.2.460 Buzdar, 2007, Preoperative chemotherapy treatment of breast cancer—a review, Cancer, 110, 2394, 10.1002/cncr.23083 Arun, 2011, Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results, Oncologist, 16, 1527, 10.1634/theoncologist.2011-0134 Shenkier, 2004, Clinical practice guidelines for the care and treatment of breast cancer: treatment for women with stage III or locally advanced breast cancer, CMAJ, 170, 983, 10.1503/cmaj.1030944 Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version), Arch Pathol Lab Med, 134, e48, 10.5858/134.7.e48 Prowell, 2012, Pathological complete response and accelerated drug approval in early breast cancer, N Engl J Med, 366, 2438, 10.1056/NEJMp1205737 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Dontu, 2003, In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells, Genes Dev, 17, 1253, 10.1101/gad.1061803 Wei, 2012, Relationship of CD44+CD24−/low breast cancer stem cells and axillary lymph node metastasis, J Transl Med, 10, S6, 10.1186/1479-5876-10-S1-S6 Mohanty, 2014, ROS-PIASγ cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors, Cell Death Dis, 5, e1021, 10.1038/cddis.2013.534 Fillmore, 2008, Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy, Breast Cancer Res, 10, R25, 10.1186/bcr1982 Saha, 2014, Contribution of the ROS-p53 feedback loop in thuja-induced apoptosis of mammary epithelial carcinoma cells, Oncol Rep, 31, 1589, 10.3892/or.2014.2993 Shen, 2008, Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells, J Pharmacol Exp Ther, 324, 95, 10.1124/jpet.107.127704 Adhikary, 2014, Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of SMAR1 in breast cancer cells, J Biol Chem, 289, 25431, 10.1074/jbc.M113.527267 Mazumdar, 2013, Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways, Apoptosis, 18, 589, 10.1007/s10495-013-0803-0 Chakraborty, 2014, Nuclear matrix protein SMAR1 represses c-Fos-mediated HPV18 E6 transcription through alteration of chromatin histone de-acetylation, J Biol Chem, 289, 29074, 10.1074/jbc.M114.564872 Potts, 2012, Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue, Lab Invest, 92, 1342, 10.1038/labinvest.2012.91 Hartkopf, 2013, The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy, Breast Cancer Res, 15, R94, 10.1186/bcr3496 Koller, 1986, Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea, N Engl J Med, 315, 1433, 10.1056/NEJM198612043152301 Pardo, 2010, An expanded Oct4 interaction network: implications for stem cell biology, development, and disease, Cell Stem Cell, 6, 382, 10.1016/j.stem.2010.03.004 Yang, 2005, Characterization of putative cis-regulatory elements that control the transcriptional activity of the human Oct4 promoter, J Cell Biochem, 96, 821, 10.1002/jcb.20588 Wu, 2006, Functional analysis of two Sp1/Sp3 binding sites in murine Nanog gene promoter, Cell Res, 16, 319, 10.1038/sj.cr.7310040 Mizutani, 2005, Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide, Life Sci, 76, 1439, 10.1016/j.lfs.2004.05.040 Minotti, 2004, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol Rev, 56, 185, 10.1124/pr.56.2.6 Linn, 1997, Expression of drug resistance proteins in breast cancer, in relation to chemotherapy, Int J Cancer, 71, 787, 10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5 Koga, 2013 Montagna, 2008, Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer, Br J Cancer, 98, 1745, 10.1038/sj.bjc.6604384 Gianni, 2009, Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer, J Clin Oncol, 27, 2474, 10.1200/JCO.2008.19.2567 Dowsett, 2008, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial, J Clin Oncol, 26, 1059, 10.1200/JCO.2007.12.9437 Linn, 2010, A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells, Genes Cancer, 1, 908, 10.1177/1947601910388271 Wang, 2010, Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway, Hepatology, 52, 528, 10.1002/hep.23692 Huang, 2014, Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening, Oncol Rep, 31, 1235, 10.3892/or.2014.2976 Boichuk, 2014, Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors, Cancer Res, 74, 1200, 10.1158/0008-5472.CAN-13-1955 Signore, 2013, Targeting apoptosis pathways in cancer stem cells, Cancer Lett, 332, 374, 10.1016/j.canlet.2011.01.013 Chen, 2014, Hyaluronan-CD44 interaction promotes c-Jun signalling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells, Mol Cancer, 13, 52, 10.1186/1476-4598-13-52 Vyhlidal, 2000, Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site, J Mol Endocrinol, 24, 329, 10.1677/jme.0.0240329 Lee, 2006, Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites, Mol Cancer Ther, 5, 2737, 10.1158/1535-7163.MCT-06-0426 Seznec, 2011, Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma, J Neurooncol, 101, 365, 10.1007/s11060-010-0266-x Ludin, 2014, Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration, and development, as well as their bone marrow microenvironment, Antioxid Redox Signal, 21, 1605, 10.1089/ars.2014.5941